Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series D | Alive

Total Raised


Last Raised

$10M | 8 yrs ago

About Cerevast Therapeutics

Cerevast Therapeutics is developing a non-invasive treatment for acute ischemic stroke known as sonothrombolysis, or SonoLysis for short. This treatment harnesses the acoustic energy from externally applied ultrasound to treat stroke-causing clots in the blood vessels of the brain. The company has developed an operator-independent ultrasonic headframe called the ClotBust-ER. This device can be rapidly and easily deployed by virtually any emergency room staff to safely administer the ultrasound energy for SonoLysis therapy.

Cerevast Therapeutics Headquarters Location

11601 Willows Road Suite 100

Redmond, Washington, 98052,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Cerevast Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Cerevast Therapeutics is included in 2 Expert Collections, including Medical Devices.


Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Cerevast Therapeutics Patents

Cerevast Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Acoustics
  • Ion channels
  • Membrane biology
patents chart

Application Date

Grant Date


Related Topics




Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics


Application Date


Grant Date



Related Topics

Ion channels, Neurophysiology, Membrane biology, Neurotechnology, Acoustics



Latest Cerevast Therapeutics News

BIO Elects New Board Officers and Members

Jun 7, 2016

June 06, 2016 09:00 PM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )--The Biotechnology Innovation Organization  (BIO) is pleased to announce the election of two new Board Officers, several new Section Governing Board Chairs, and 21 new members of its Board of Directors, all voted upon at this year’s 2016 BIO International Convention. Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics, was elected to serve as BIO’s Board Treasurer; and David Meeker, Chief Executive Officer, Genzyme/Sanofi, was elected to serve as Board Secretary. Ron Cohen, President & CEO, Acorda Therapeutics, was re-elected to another term as Chair. In addition, BIO announces the election of Alan Shaw, President & CEO, Calysta, as the new Chair of the Industrial & Environmental Section Governing Board; Michael Narachi, President & CEO, Orexigen Therapeutics, as the new Chair of the Emerging Companies Section Governing Board; and Eddie Sullivan, President & CEO, SAB Biotherapeutics, as the new Chair of the Food & Agriculture Section Governing Board. “We welcome our new officers, Board leaders, and Board Members, and are looking forward to working with them to create a more favorable policy, legislative, and business development environment for the global biotech industry,” said Jim Greenwood, BIO President & CEO. “This newly-constituted Board of Directors brings significant industry experience and passion that will serve BIO and its members well.” Greenwood also thanked BIO’s departing Board Members, saying, “BIO is deeply appreciative to departing Board Members for their dedication and commitment over the years.” BIO’s Board also elected a new slate of Executive Committee members for the 2016-2017 term. They are: Ron Cohen, President & CEO, Acorda Therapeutics – Board/Health Section Chair Bradford Zakes, Chief Executive Officer, Cerevast Therapeutics – Board Treasurer David Meeker, Chief Executive Officer, Genzyme/Sanofi – Board Secretary Paul Hastings, President & CEO, OncoMed Pharmaceuticals – Health Section Vice Chair Alan Shaw, President & CEO, Calysta – Industrial & Environmental Section (IES) Governing Board Chair Tjerk de Ruiter, Chief Executive Officer, Corbian – IES Vice Chair Michael Narachi, President & CEO, Orexigen Therapeutics – Emerging Companies Section (ECS) Governing Board Chair Eddie Sullivan, President & CEO, SAB Biotherapeutics – Food & Agriculture Section (FAS) Governing Board Chair Philip Miller, Vice President Global Regulatory and Government Affairs, Monsanto – Food & Agriculture Section (FAS) Governing Board Vice Chair Rachel King, Chief Executive Officer, GlycoMimetics – Immediate Past Chair Alex Azar, President of Lilly USA, Eli Lilly and Company – At-Large Ian Clark, CEO & Head of North American Commercial Operations, Genentech/Roche – At-Large Doug Doerfler, President & CEO, MaxCyte – At-Large Julie Gerberding, Executive Vice President for Strategic Communications, Global Public Policy & Population Health, Merck – At-Large Perry Karsen, Chairman & CEO, Jounce Therapeutics – At-Large John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals – At-Large Richard Pops, Chairman & CEO, Alkermes – At-Large Jay Siegel, Chief Biotechnology Officer & Head of Scientific Strategy & Policy, Johnson & Johnson – At-Large The full BIO Board of Directors is comprised of the elected Directors serving on each of BIO’s Section Governing Boards. The newly-elected Board Members from these Sections are: Emerging Companies Section Governing Board Julie Smith, President & CEO, Raptor Pharmaceuticals Steven Paul, President & CEO, Voyager Therapeutics Food & Agriculture Section Governing Board Brian Barker, General Manager, US Seeds, Dow AgroSciences Rick Van Genderen, Director, Business Management, BASF Plant Science, BASF Health Section Governing Board Albert Bourla, Group President of Global Innovative Pharma and Global Vaccines, Oncology and Consumer Healthcare Business, Pfizer Habib Dable, President, U.S. Pharmaceuticals, Bayer Mark Enyedy, President & CEO, ImmunoGen Bill Hinshaw, Executive Vice President and Head, US, Novartis Oncology Joe LaRosa, Senior Vice President, General Counsel and Secretary, Regeneron Jeremy Levin, Chairman of the Board & CEO, Ovid Therapeutics Kiran Mazumdar-Shaw, Chairperson and Managing Director, Biocon Limited David Nicholson, Chief R&D Officer, Allergan James Sapirstein, Chief Executive Officer, ContraVir Julie Smith, President & CEO, Raptor Pharmaceuticals Kathleen Tregoning, Senior Vice President, Corporate Affairs, Biogen Neil Warma, President & CEO, Opexa Therapeutics Industrial & Environmental Section Governing Board Jennifer Holmgren, Chief Executive Officer, LanzaTech John Melo, President & CEO, Amyris About BIO BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention , the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter . Upcoming BIO Events

Cerevast Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Cerevast Therapeutics Rank

  • When was Cerevast Therapeutics founded?

    Cerevast Therapeutics was founded in 2009.

  • Where is Cerevast Therapeutics's headquarters?

    Cerevast Therapeutics's headquarters is located at 11601 Willows Road, Redmond.

  • What is Cerevast Therapeutics's latest funding round?

    Cerevast Therapeutics's latest funding round is Series D.

  • How much did Cerevast Therapeutics raise?

    Cerevast Therapeutics raised a total of $23.32M.

  • Who are the investors of Cerevast Therapeutics?

    Investors of Cerevast Therapeutics include Genstar Capital, Kearny Venture Partners, Haiyin Capital and Qualifying Therapeutic Discovery Project.

  • Who are Cerevast Therapeutics's competitors?

    Competitors of Cerevast Therapeutics include Armgo Pharma, KIYATEC, Sorrento Therapeutics, Promedior, Somnus Therapeutics and 11 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).


Allozyne is a protein optimization company committed to the development of improved biological therapeutics to treat multiple areas of unmet medical need. Allozyne's two technology platforms enable the incorporation of amino acids analogues, at any specified position, into existing biologics leading to improved efficacy, tolerability and pharmacology.

Seaside Therapeutics

Seaside Therapeutics is creating new drug treatments to correct or improve the course of Fragile X Syndrome, autism and other disorders of brain development.

Sarentis Therapeutics

Sarentis is a start-up biopharmaceutical company focused on the development of therapeutics for the treatment of pain.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.